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Glossary: 
visceral leishmaniasis: the vector–borne disease caused by infection with either Leishmania 
donovani or L. infantum  
asymptomatic: infection in the absence of clinical signs or symptoms 
super-spreader: infected dogs, or humans, that make a disproportionally high contribution to 
ongoing parasite transmission to the intermediate sand fly host 
rK39: the gold standard recombinant, chimeric polyprotein rK39 used to confirm VL 
DPP CVL: Dual-Path Platform technology (DPP®CVL rapid test) for the serodiagnosis of canine 
visceral. A lateral flow-based test that detects canine IgG antibodies against the rK28 antigen. 
 
 
  
Abstract 
Visceral leishmaniasis (VL) is a life-threatening outcome of Leishmania infantum or L. donovani 
infection. Dogs are the primary domestic reservoir of L. infantum parasites and ownership of 
infected dogs increases the risk of human VL. Controlling infection within dog populations is 
regarded as critical to VL management in endemic countries, both preventing progression of 
canine disease and limiting parasite transmission to humans and dogs. Here we discuss various 
strategies that are used to diagnose canine visceral leishmaniasis (CVL) and the possibilities of 
adapting these for use within population screening and control programs. In addition, given the 
variable transmissibility of L. infantum to the sand fly vector, we outline some possibilities for 
the preferential identification of “super-spreader” dogs among the overall infected population.  
 
 
 
 
  
Leishmania infection and visceral leishmaniasis 
Visceral leishmaniasis (VL) is a vector–borne disease characterized by prolonged fever, 
wasting, splenomegaly, and hepatomegaly, resulting in >90% case–fatality within two years in 
the absence of treatment [1]. Estimates of the number of new human VL (HVL) cases per year 
range from 25,000 to 200,000 accounting for underreporting [2, 3], and although therapeutic 
drug options are available, the control portfolio to prevent transmission are limited. VL due to 
Leishmania donovani is considered anthroponotic, with likely zoonotic transmission in East 
Africa, whereas VL due to L. infantum is considered a zoonosis reliant on domestic dogs as the 
sole proven reservoir [4, 5] (Figure 1). L. infantum infection of dogs can lead to canine VL (CVL), 
a multisystemic disease with a range of clinical signs typically including dermatitis, 
lymphadenomegaly, general muscular atrophy, and renal disease [6]. 
Anthroponotic VL has been targeted for elimination as a public health problem (defined 
as an incidence of <1 VL case/10,000 people per year in specified geographical scales) in the 
Indian subcontinent by 2020 [7]. Substantial investments and political advocacy have been used 
to implement novel case detection strategies, rapid diagnostic testing and vector control 
activities [1, 7]. In contrast, despite the large burdens typically in young children, efforts to 
reduce zoonotic VL (ZVL) in endemic regions of Latin America, East Africa, and central Asia are 
less advanced [3]. The zoonotic nature of L. infantum transmission suggests that controlling 
infection within dog populations, is a reasonable strategy to reduce infection rates in humans 
[8, 9].  The majority of ZVL cases in the Americas occur in Brazil [3], where intervening measures 
of indoor residual spraying (IRS) and dog test-and-slaughter are national policies [10]. The test-
and-slaughter policy has, however, been legally challenged in some Brazilian states with the 
outcome that treatment is now permitted. There is, however, a lack of evidence that these 
strategies have significantly reduced canine or human ZVL incidence [11, 12], and alternative or 
complimentary control methods are presently under evaluation [13-15]. Preventative measures 
against canine infection or disease include the use of topical or oral insecticides, and canine 
anti-Leishmania vaccination, that are shown to provide varying levels of protection to individual 
dogs [16]. That any canine control option corresponds to a reduction in human infection still 
requires well designed randomized field trials [17]. 
Given that many more asymptomatic than symptomatic canine (and human) 
Leishmania infections are identified in cross-sectional surveys, surveillance for both infection 
and disease are essential for the future success of control programs [6]. In this article, we 
discuss various diagnostic strategies, with emphasis on current and new developments in 
antigen-based serological diagnostic tests, their applications, and performance requirements 
for different settings. In doing so, we identify current issues and research priorities.  
 
Diagnosing infection and CVL 
The clinical signs of CVL are quite general and therefore not particularly useful for 
detecting symptomatic infection or differentiating Leishmania from other etiologies [16]. 
Numerous tools are, however, available to aid the diagnosis of both canine and human 
infection, covering an array of direct and indirect detection methods (Figure 2). Direct methods 
include xenodiagnosis and parasite observance in ex vivo cultures, or recognition of 
amastigotes following biopsy or microscopy. Parasite genome equivalents can be detected by 
molecular DNA-based techniques. In clinical settings, confirmation of cure requires 
demonstrating absence of tissue parasites, which depends on the sensitivity of methods and 
sample type to detect low-level parasite burdens. Leishmania burdens generally decline during 
treatment [18-20], although residual parasites were detected in up to 50% of human patients 
that were considered cured based on the resolution of symptoms [19, 21]. Similarly, alleviation 
of symptoms and decreased parasite loads are considered indicators of treatment success in 
CVL patients, though complete parasitological clearance is often not achieved (reviewed by 
[22]).  Some diagnostic techniques used routinely in research laboratories are not suited for 
widespread use in field settings. For example, PCR/qPCR requires nucleic acid extraction, 
amplification in a thermocycler and gel-based analyses to demonstrate specific gene 
expression, each step requiring specialist technical conditions; it may require invasive sample 
collection and is generally costly. Point-of-care assays such as loop-mediated isothermal 
amplification (LAMP) and nanoparticle-based lateral flow biosensors for DNA are being 
developed to address some of these issues [23-28]. The commercially available Leishmania 
OligoC-TesT kit that incorporates standardized PCR reagents with rapid oligochromatographic 
dipstick detection of the PCR products provides greater sensitivity for polysymptomatic and 
oligosymptomatic dogs than for asymptomatic dogs, a trend observed for various other 
qualitative PCR methods [29]. Real-time qPCR typically provides the highest sensitivity. Among 
the recent advances towards development of a field applicable PCR type test for CVL, is a 
combined, duplex qPCR protocol that detects L. infantum kinetoplast (k)DNA simultaneously 
with host (canine 18S) rRNA in a single tube, in a ready-to-use (gelified and freezer-free) format 
[30]. Duplexing of these qPCR protocols permits generation of quality-controlled results with 
reduced overall cost relative to running each assay separately. Higher test sensitivities (e.g. 
92.9%) were achieved using splenic aspirates than skin or blood samples (50% and 35.7%, 
respectively) but relies on invasive sampling [30]. Similarly, an in-clinic point-of-care PCR for the 
diagnosis of canine Leishmania infection (PCRun; Biogal Galed Labs ACS) provided reliable 
confirmation of CVL infection, but was constrained by an inverse correlation between assay 
sensitivity and simplicity of sample collection (ranging from 58.8% in lymph node aspirates to 
10.0% in blood) [31]. 
Despite molecular advances, indirect approaches centered on immune responses to 
Leishmania antigens still provide the most tangible possibilities to support CVL and HVL diagnosis 
in low resource settings. While dogs resistant to developing CVL typically have undetectable or 
low, often transient, anti-Leishmania antibody responses, non-resistant dogs that develop signs 
of CVL typically have high serum antibody titers that positively correlate with tissue parasite 
density and clinical severity [32-34]. Therefore, antibody-based test sensitivities are unlikely to 
be similar for asymptomatic and symptomatic infections [35]. High initial antibody titers against 
crude Leishmania antigen (CLA) are associated with increased risk of developing clinical signs 
[36], and positive rk39 rapid diagnostic test (RDT) results are strongly associated with high 
infection levels and disease progression [35]. In humans, high anti-Leishmania antibody levels 
during the asymptomatic infection phases are similarly indicative of likely progression to VL: in 
India, 12% of individuals with direct agglutination test (DAT) titers >25,600 subsequently 
developed clinical disease, compared to only 1% of those with low but positive DAT results [37]. 
Likewise, in Bangladesh 29% of strongly rK39-seropositive individuals at study intake progressed 
to VL compared to less than 4% of low seropositive or seronegative individuals [38]. Comparable 
estimates using alternative antibody threshold definitions were reported by others [37].  
Diagnostic tests require different attributes dependent upon the particular application. 
High sensitivity is required to prevent inadvertent introduction of infected human or canine 
blood into blood banks; to monitor success of treatment/intervention of either HVL or CVL; to 
detect spread of Leishmania-infected dogs across international borders, and for epidemiological 
studies or trials to differentiate infected and non-infected individuals in the population. 
Refinement from the use of crude Leishmania extracts to purified recombinant antigens 
includes several recombinant antigen-based immunoassays, foremost among these, are 
platforms based on the chimeric polyprotein rK39 used to confirm HVL and CVL infection [39-
41]. The incorporation of rK39 into lateral flow-based rapid tests (Kalazar DetectTM, InBios 
International Inc., Seattle, WA) provided a simple field-friendly format capable of providing 
diagnosis of HVL at the point of care [42, 43]. Modifications of the rK39 antigen yielded a next 
generation rK28 RDT-based rapid diagnostic test for enhanced diagnosis of HVL in Africa (Onsite 
Leishmania Ab Combo Rapid Test, CTK Biotech, San Diego, CA) [44-46]. A dog-specific variant of 
this, DPP® CVL (Chembio Diagnostics, Medford, NJ), retains high performance  [47-49]. and is 
now established within the diagnostic recommendations of the Brazilian Ministry of Health. 
Removal of the laboratory requirements associated with ELISA render these lateral flow-based 
tests applicable in a wider array of settings. 
New antigen targets and refinements to provide further incremental improvements in 
the diagnostic performance of antibody-detection tests are being proposed. For example, the 
use of recombinant protein rLc36 in ELISA enabled differentiation of positive and negative sera 
and showed a sensitivity of 85% and specificity of 71% [50]. Combinatorial approaches can 
enhance sensitivity, while continued screening of genomic expression libraries or adapted 
bioinformatics searches are providing new hits. Indeed, combining rKLO8 and rK26 increased 
sensitivity and specificity (85% and 93%, respectively) over the levels achieved by either antigen 
alone (sensitivities and specificities of 68% and 92% for KLO8, and of 77% and 91% for rK26, 
respectively) [51]. Following selection from a L. infantum amastigote cDNA library, rLci1A and 
rLci2B were combined and incorporated into a prototype rLci1A/rLci2B dual path platform rapid 
test. Evaluation of 154 sera from CVL dogs across endemic regions in Brazil yielded performance 
specifications comparable to those attained with DPP® CVL (sensitivity of 87% and specificity of 
100% for rLci1A/rLci2B DPP versus 88% sensitivity and 97% specificity for DPP® CVL, 
respectively) [52]. Immunoproteomics identified LiHyD, a hypothetical protein, that yielded 
perfect (100%) sensitivity and specificity when tested by ELISA against sera from 44 CVL and 9 
asymptomatic L. infantum-infected dogs [53]. In terms of detecting disease, novel protein-
coding gene fragments that had not previously been studied were used to generate 
polyproteins that in serum ELISA demonstrated better performance to detect CVL than HVL: no 
effective detection of HVL (26-52% sensitivity) was demonstrated whereas 48-91% of CVL dogs 
were detected. These three antigens performed better than rK39 in this particular evaluation 
panel of 46 CVL sera [54]. 
In addition to novel targets, practical advancements are being sought. As mentioned, 
lateral flow-based tests can be used in a wide array of settings and prototype rLci1A/rLci2B DPP 
have been generated [52]. Removal of the laboratory requirements expands applicability and 
other examples fulfill this criterion. Covalent coupling of a k28-like protein onto polystyrene 
latex to provide a substrate for antibody binding yielded an agglutination test capable of 
producing visual results within 5 minutes, with sensitivity, specificity and diagnostic accuracy of 
78%; 100% and over 80%, respectively [55]. Besides formatting, adjustments (or simply 
alternative use) to generate results from other body fluids are also being examined. Anti-rK28 
antibodies are readily detectable in the urine of HVL patients, with performance only marginally 
lower than that obtained with serum [56]. It is likely that similar results would be achieved from 
infected canine urine. Saliva presents another easy way to collect alternative analyte, and a 
time-resolved immunofluorometric assay (TR-IFMA) quantifying anti-rK39 IgG2 antibodies 
indicated that greater discrimination between seropositive and seronegative dogs was achieved 
using saliva than serum [57]. 
 
Detecting Leishmania infection in surveillance and control programs 
VL surveillance programs and epidemiological studies that aim to detect Leishmania 
infection pertinent to either HVL or CVL control require tests with high sensitivity. Under 
specific conditions, such as reservoir control programs that deploy a test-and-slaughter policy, 
low compliance by dog owners fearing the potential removal of their apparently healthy but 
seropositive dogs has a major impact on program success. Thus, high specificity to differentiate 
clinically suspect cases from other etiological agents is of paramount importance, as is the need 
for high sensitivity to detect asymptomatic infections. In the advent of treatment of CVL, 
prompt and specific differential diagnosis is required by veterinary clinics to indicate 
Leishmania chemotherapy. On the other hand, for prevention of canine infection, high test 
sensitivity and specificity to confirm lack of Leishmania infection are required prior to 
application of preventative topical or oral insecticides, or canine vaccination.  
For both humans and dogs, tissue parasite numbers are generally low in asymptomatic 
L. donovani or L. infantum infections [58]. An Indian study recorded an average 500-fold lower 
blood parasite loads in asymptomatic L. donovani-infected individuals than in HVL patients [59], 
but indicated that asymptomatic individuals with higher parasite loads were at increased risk of 
developing VL [60]. The most sensitive technique for diagnosis of infection in dogs is qPCR, with 
qPCR results often, but not always, becoming positive in early infection before seroconversion 
occurs [34, 61]. Comparative evaluations indicate that seroprevalence may be below 30% in 
dog populations where prevalence of DNA detection by PCR can be as high as 80% [6, 62, 63]. 
Comparison between foci and tests is difficult but annual incidence estimates in Europe appear 
to vary greatly (between 40-92%) [61, 64, 65]. Test standardization for surveillance would help 
in data interpretation, but detection of blood or tissue parasites by PCR/qPCR is currently not 
operational within population-based surveillance programs for reasons discussed above. 
Tests detecting immune responses appear more tenable for larger surveillance 
programs than many other current methods. Dogs resistant to developing CVL exhibit 
protective immunity mediated by CD4+ T helper 1 cell responses with prominent expression of 
IFN-y and IL-4 cytokines in association with Th2 regulatory responses [32]. Among immune-
based assays for HVL, Leishmania-specific T cell recall tests have been develop that range from 
the leishmanin skin test, which induces an in vivo delayed type hypersensitivity (DTH) response 
[66, 67], to ex vivo assays measuring secretion of cytokines into stimulated blood [68, 69]. 
Compared to cell-based assays, serological antibody-detection tests, including indirect 
fluorescent antibody test (IFAT), direct agglutination test (DAT) and ELISA, are relatively cheap 
and, although generally more sensitive at detecting symptomatic than asymptomatic infections 
[70], their durability and practicality is considered an advantage particularly for low resource 
settings. Simple strategies can also render DPP CVL semi-quantitative, providing a more 
detailed diagnostic assessment and potentially a broader use in monitoring [71]. Truly 
asymptomatic infections usually revert to seronegative and/or low to moderate titers within 
months of infection and accurate quantification of responses is important in capturing this [72]. 
The Brazilian Ministry of Health changed the diagnostic protocol for CVL in December 
2011, with the current protocol reducing false-positive results relative to the previous protocol. 
A key action within the program has traditionally included euthanasia of all Leishmania 
seropositive or confirmed infected dogs, and not only those that displayed clinical signs. This 
has, however, been legally challenged in several states with the courts generally preferring the 
option of treatment similar to the widely accepted practice in Europe. The current criteria of 
canine infection requires firstly a positive result in DPP CVL, followed by another positive result 
in a confirmatory ELISA using soluble antigens of L. infantum promastigotes. Recent studies 
have demonstrated that adjusting the sequence of testing, from that used in the current 
protocol (DDP followed by ELISA) to the reverse order (ELISA followed by DDP), did not cause a 
significant alteration in the final number of infected dogs detected [73, 74]. Sensitivity and 
specificity were, respectively, 82.3% and 92.8% for DDP, and 85% and 92.3% for ELISA [74]. 
However, conflicting test results lead to interpretation issues, which is perhaps inevitable as the 
tests target different antigens and have variable levels of sensitivity and specificity. Based on 
the surveillance protocol, of 1130 dogs first examined by DPP CVL under field conditions in 
Minais Gerais, then confirmed by lab-based ELISA evaluation, seroprevalence was assessed at 
7.8% (8/101).  This rate was slightly lower than the 8.9% (101/1130) that could be attributed by 
a positive result in either the DPP CVL test or ELISA (in addition to a lab-based DPP CVL) [75]. It 
was noteworthy, but perhaps not too surprising, that in animals initially positive by DDP CVL, 
seroconversion was more frequent in dogs that in follow-up testing were ELISA indeterminate, 
compared to those that were clearly ELISA negative. In another study surveying 975 dogs with 
DPP, ELISA and qPCR, almost 1 in 5 (174/887; 19.6%) of the dogs that were negative in DPP CVL 
tested positive by qPCR of either blood or lymph node aspirates [76]. Further evaluation in a 
second cohort of the DPP negative dogs revealed that almost half (36/79; 45.6%) were 
positively detected in qPCR of at least one of their blood, lymph node or conjunctival swab 
samples that were collected.  
 
Identifying infectious individuals as a means toward controlling transmission 
A major question for HVL control efforts on the Indian subcontinent is whether people 
with asymptomatic infection are sufficiently infectious to sand flies to represent a significant 
reservoir for L. donovani [77]. While it has been demonstrated that HVL and post kala-azar 
dermal leishmaniasis (PKDL) patients can be highly infectious [4, 78], the epidemiological 
significance of asymptomatic L. donovani infection in transmission remains unclear. Given that 
there appear to be between 4- to 17-fold more asymptomatic individuals than HVL patients, 
some believe that even if a subset of asymptomatic individuals are infectious at a very low 
level, the asymptomatic population can make a critical contribution to ongoing transmission 
[72, 79-83]. By cross-sectional study, parasites have been detected in human blood in up to 
58% of asymptomatic infections with L. infantum [19, 58, 84] and L. donovani [59, 85]. Large 
variance also occurs in tissue parasite loads. Fourteen percent of 4695 asymptomatic Ethiopians 
were qPCR-positive in blood, of which 3.2% had high genome equivalent counts [85], suggesting 
that a small proportion of individuals may have a disproportionate role in onward transmission. 
In longitudinal studies, 83% (80/97) of asymptomatic L. infantum-infected individuals living in 
an active transmission region of Brazil tested PCR-positive during 6 years follow-up [86]. 
In the case of zoonotic transmission, whilst it is clear that both asymptomatic and 
symptomatic dogs can infect vectors such as Lu. longipalpis, their relative roles in maintaining 
endemic transmission is best explored by mathematical modelling [5, 87-91]. Meta-analysis of 
the relatively few canine xenodiagnosis studies [35] indicate that the proportion of 
symptomatic dogs that are infectious is generally high (80%), and that this proportion may be 
higher in Europe than in Latin America (86% versus 45%). The meta-analysis also indicated that 
29% of dogs reported as asymptomatic were also infectious, although the definition of true 
asymptomatic infection requires careful clinical, biochemical and hematological classification 
during infection development. While some longitudinally followed dogs contribute little or 
nothing to transmission, there is usually a small fraction of infected dogs that contribute 
disproportionately: current studies indicate that 15% to 44% of dogs are responsible for more 
than 80% of all sand fly infections [5, 92, 93]. A high transmission potential corresponds to skin 
and bone marrow Leishmania parasite loads being higher relative to loads in less infectious and 
non-infectious dogs [94]. Such animals are considered “super-spreaders”, as noted similarly in 
other infection systems [95-97].  
An alternative to blanket intervention programs against dogs may be to target those 
dogs that are most infectious to the sand fly vector, as opposed to targeting L. infantum 
infection or CVL per se. To date, attempts to use serological tests to specifically detect 
infectious individuals have been limited [92, 96], and as mentioned above, high test specificity 
is required to better inform dog owners and ensure compliance with control program 
recommendations. One longitudinal study showed high sensitivities for identifying highly 
infectious dogs with rK39 and CLA (79% and 97%, respectively), but low specificity for the 
detection of non-infectious dogs (50% and 13%, respectively). Alternative thresholds for 
defining positive results derived from receiver operating characteristic curve analysis improved 
the specificity to 68% with respect to non-infectious dogs, and provided an 82% sensitivity for 
predicting highly infectious dogs; differentiation of mildly infectious dogs from non-infectious 
dogs (both contributing relatively little to transmission in xenodiagnosis) was not achieved [92]. 
Similarly in another study, evaluating multiple current serological tests (ELISA, IFAT80, DPP CVL, 
rK39 tests, fast agglutination screening tests (FAST), and DAT) failed to discriminate those 
dogs that transmitted L. infantum from those that did not [98]. Further longitudinal evaluations 
of diagnostic tests to detect the epidemiologically important infectious portions of the infected 
CVL and HVL populations are urgently needed.  
 
Concluding remarks 
CVL is an important veterinary complication that not only deserves attention in its own 
right but could potentially be highly informative for HVL control programs (see Outstanding 
Questions). Control of infection in dogs in L. infantum-endemic regions would  likely create the 
additional benefit of limiting a critical reservoir that maintains the threat of human infection 
and disease. As discussed, many tools currently used to diagnose CVL are now being evolved to 
allow identification and quantification of infection irrespective of symptoms, and both 
serological and molecular assays are being adapted to suit field conditions. Test attributes have 
to be tailored to be fit-for-purpose, conversely, test standardization is desirable to facilitate 
comparative interpretation and for meta-analyses. As alternative preventative measures are 
being evaluated to combat transmission, there are opportunities to develop immunological and 
molecular assays to identify infectious, in addition to infected and diseased individuals.   
  
Figure Legends 
Figure 1. Transmission of VL-causing Leishmania among dogs and humans. A Venn diagram 
depicting the progression of Leishmania-infected dogs and/or humans to an infectious state 
culminating in presentation of VL. While L. infantum can circulate in, and be transferred 
between, dog and human populations via sand fly vectors, L. donovani is limited to human 
populations. 
 
Figure 2. Diagnostic and detection strategies. The progression of diagnostic strategies from 
direct detection methods to indirect, antibody-detection techniques is depicted. As antibody-
detection methods are refined, the possibility of using “simpler-to-collect” (i.e., less invasive) 
samples that are more permissive for large-scale surveillance programs is presenting 
themselves. 
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Highlights 
 Visceral leishmaniasis (VL) is an important disease of dogs and humans, with dogs being the 
primary domestic reservoir of L. infantum parasites.  
 Detection of diseased, infected and parasite-transmitting “super-spreader” dogs is likely critical 
for control 
 Dependent upon scale, direct and indirect detection methods can be used for surveillance 
 Novel molecular assays with point-of-care potential are emerging 
 New antigen targets are being characterized to enhance performance of serological assays 
 Adaptation to provide point-of-care serological tests to permit Leishmania detection and 
facilitate large-scale screening programs 
 
Outstanding questions 
 Does control of the parasite reservoir in dogs impact on the incidence of human infection and 
HVL? 
 Are any tests capable of differentiating between diseased, infected and parasite-transmitting 
“super-spreader” dogs? 
 Can novel molecular assays be implemented in large-scale screening programs? 
 Does asymptomatic infection elicit sufficiently potent antibody responses to permit detection? 
 Can new antigens enhance the performance of serological assays? 
 Are saliva and urine capable of providing performance levels in antibody-detection tests similar 
to those achieved with serum? 
 Can tests developed for canine VL be informative for human VL? 
 How are canine test-and-control options best deployed to provide a protective community 
effect?  
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